
Overview
Enamine Pl supplies compound libraries, building blocks and screening collections for drug discovery. Its services include custom and library synthesis, CADD, biology support and integrated drug discovery.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News

Enamine and Ewha Partner to Close the Loop Between AI Design and Real-World Chemistry
Strategic MOU connects AI-driven design with billions of make-on-demand molecules, rapid synthesis and in-house biology, and builds a new scientific bridge between Korea and Ukraine
SyntheticGestalt and Enamine Build the World’s Largest Experimentally Validated AI-driven Chemical Data Ecosystem
Tokyo, Japan, and Kyiv, Ukraine — 3 August 2026
ANTARES project launch: Artificial Intelligence aims to speed up the search for new antibacterials
Braunschweig, Frankfurt, Hamburg, Germany – July 23, 2026
Leveraging Public Infrastructure for Private Innovation: Enamine and PAL Align
Collaboration leverages PAL’s public research facilities and Enamine’s compound libraries and fragment progression support to accelerate fragment-based lead discovery (FBLD).
Enamine Strengthens Its Sustainable Procurement Program in 2026
In 2026, Enamine’s Sustainable Procurement Program is reaching a new level of maturity and impact. Building on many years of close cooperation with suppliers – and reinforced by global best practices – the Company is further strengthening its approach to responsible and sustainable procurement across the entire supply chain.
Chemspace, Enamine, and Paul Scherrer Institute Launch a Joint Service for Fragment-Based Lead Discovery
Kyiv, Ukraine and Villigen, Switzerland , April 7, 2026. Chemspace, a drug discovery engine providing machine learning-guided support for hit identification, hit to lead, and lead optimization using the largest purchasable collection of chemicals and biologics, Enamine, a leading provider of small molecules and drug discovery services, and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, have announced today a strategic…
Industry
Bank accounts
Registered as a VAT taxpayer on 2023-05-24. Active
09 2490 0005 0000 4530 0003 2124
33 2490 0005 0000 4612 0003 5817
37 2490 0005 0000 4600 0002 8472
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Authorized Representatives
Manner of representation
The company is represented by each member of the management board acting independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Zbigniew Marek Darżynkiewicz (46) | 5 | $67.53 | 5% |
Naukovo-Vyrobnyche Pidpryiemstvo Yenamin” Tovarystvo Z Obmezhenoiu Vidpovidalnistiu | 95 | $1,283.09 | 95% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MabionS.A. | $3,856,855.85 | mabion.eu | ||
| Aslab ScienceP.S.A. | $1,504,132.17 | aslabsci.com |
FAQ
Last updated: 2026-06-25